CSL et Alentis annoncent un partenariat mondial visant à développer et à mettre sur le marché le lixudebart pour le traitement de maladies rares des reins et du foie

CSL and Alentis Therapeutics announced an agreement under which Alentis will receive an initial $355 million and could receive up to $1.2 billion in commercial milestone payments. The agreement also includes global profit sharing; further terms and the assets involved are not specified in the provided text.